Literature DB >> 7888294

Characterisation of the cytochrome P450 enzymes involved in the in vitro metabolism of granisetron.

J C Bloomer1, S J Baldwin, G J Smith, A D Ayrton, S E Clarke, R J Chenery.   

Abstract

1. The metabolism of granisetron was investigated in human liver microsomes to identify the specific forms of cytochrome P450 responsible. 2. 7-hydroxy and 9'-desmethyl granisetron were identified as the major products of metabolism following incubation of granisetron with human liver microsomes. At low, clinically relevant, concentrations of granisetron the 7-hydroxy metabolite predominated. Rates of granisetron 7-hydroxylation varied over 100-fold in the human livers investigated. 3. Enzyme kinetics demonstrated the involvement of at least two enzymes contributing to the 7-hydroxylation of granisetron, one of which was a high affinity component with a Km of 4 microM. A single, low affinity, enzyme was responsible for the 9'-desmethylation of granisetron. 4. Granisetron caused no inhibition of any of the cytochrome P450 activities investigated (CYP1A2, CYP2A6, CYP2B6, CYP2C9/8, CYP2C19, CYP2D6, CYP2E1 and CYP3A), at concentrations up to 250 microM. 5. Studies using chemical inhibitors selective for individual P450 enzymes indicated the involvement of cytochrome P450 3A (CYP3A), both pathways of granisetron metabolism being very sensitive to ketoconazole inhibition. Correlation data were consistent with the role of CYP3A3/4 in granisetron 9'-desmethylation but indicated that a different enzyme was involved in the 7-hydroxylation.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7888294      PMCID: PMC1364919          DOI: 10.1111/j.1365-2125.1994.tb04397.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  34 in total

1.  Use of quinidine inhibition to define the role of the sparteine/debrisoquine cytochrome P450 in metoprolol oxidation by human liver microsomes.

Authors:  S V Otton; H K Crewe; M S Lennard; G T Tucker; H F Woods
Journal:  J Pharmacol Exp Ther       Date:  1988-10       Impact factor: 4.030

2.  Purification and characterization of liver microsomal cytochrome P-450 from untreated male rats.

Authors:  Y Funae; S Imaoka
Journal:  Biochim Biophys Acta       Date:  1987-12-07

3.  Pharmacokinetics and tolerability of ascending intravenous doses of granisetron, a novel 5-HT3 antagonist, in healthy human subjects.

Authors:  A Allen; C C Asgill; D M Pierce; J Upward; B D Zussman
Journal:  Eur J Clin Pharmacol       Date:  1994       Impact factor: 2.953

4.  Tolbutamide hydroxylation by human liver microsomes. Kinetic characterisation and relationship to other cytochrome P-450 dependent xenobiotic oxidations.

Authors:  J O Miners; K J Smith; R A Robson; M E McManus; M E Veronese; D J Birkett
Journal:  Biochem Pharmacol       Date:  1988-03-15       Impact factor: 5.858

5.  Human P450PCN1: sequence, chromosome localization, and direct evidence through cDNA expression that P450PCN1 is nifedipine oxidase.

Authors:  F J Gonzalez; B J Schmid; M Umeno; O W Mcbride; J P Hardwick; U A Meyer; H V Gelboin; J R Idle
Journal:  DNA       Date:  1988-03

6.  Oxidation of quinidine by human liver cytochrome P-450.

Authors:  F P Guengerich; D Müller-Enoch; I A Blair
Journal:  Mol Pharmacol       Date:  1986-09       Impact factor: 4.436

7.  Biotransformation of caffeine, paraxanthine, theophylline, and theobromine by polycyclic aromatic hydrocarbon-inducible cytochrome(s) P-450 in human liver microsomes.

Authors:  M E Campbell; D M Grant; T Inaba; W Kalow
Journal:  Drug Metab Dispos       Date:  1987 Mar-Apr       Impact factor: 3.922

8.  Quinidine and the identification of drugs whose elimination is impaired in subjects classified as poor metabolizers of debrisoquine.

Authors:  C J Speirs; S Murray; A R Boobis; C E Seddon; D S Davies
Journal:  Br J Clin Pharmacol       Date:  1986-12       Impact factor: 4.335

9.  Ethoxy-, pentoxy- and benzyloxyphenoxazones and homologues: a series of substrates to distinguish between different induced cytochromes P-450.

Authors:  M D Burke; S Thompson; C R Elcombe; J Halpert; T Haaparanta; R T Mayer
Journal:  Biochem Pharmacol       Date:  1985-09-15       Impact factor: 5.858

10.  A direct, highly sensitive assay for cytochrome P-450 catalyzed O-deethylation using a novel coumarin analog.

Authors:  J G DeLuca; G R Dysart; D Rasnick; M O Bradley
Journal:  Biochem Pharmacol       Date:  1988-05-01       Impact factor: 5.858

View more
  15 in total

Review 1.  Granisetron in the control of radiotherapy-induced nausea and vomiting: a comparison with other antiemetic therapies.

Authors:  Petra Feyer; M Heinrich Seegenschmiedt; Maria Steingraeber
Journal:  Support Care Cancer       Date:  2005-07-26       Impact factor: 3.603

Review 2.  Comparative Pharmacology and Guide to the Use of the Serotonin 5-HT3 Receptor Antagonists for Postoperative Nausea and Vomiting.

Authors:  Anthony L Kovac
Journal:  Drugs       Date:  2016-12       Impact factor: 9.546

Review 3.  Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6 genotype and use of ondansetron and tropisetron.

Authors:  G C Bell; K E Caudle; M Whirl-Carrillo; R J Gordon; K Hikino; C A Prows; A Gaedigk; Jag Agundez; S Sadhasivam; T E Klein; M Schwab
Journal:  Clin Pharmacol Ther       Date:  2017-04-06       Impact factor: 6.875

4.  The pharmacokinetics of granisetron, a 5-HT3 antagonist in healthy young and elderly volunteers.

Authors:  A Allen; P Crome; C C Davie; M Davy; R W Jones; D M Pierce; J Upward; P Wijayawardhana
Journal:  Eur J Clin Pharmacol       Date:  1995       Impact factor: 2.953

Review 5.  Chemical inhibitors of cytochrome P450 isoforms in human liver microsomes: a re-evaluation of P450 isoform selectivity.

Authors:  Siamak Cyrus Khojasteh; Saileta Prabhu; Jane R Kenny; Jason S Halladay; Anthony Y H Lu
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2011-02-19       Impact factor: 2.441

Review 6.  Selective serotonin 5-HT3 receptor antagonists for postoperative nausea and vomiting: are they all the same?

Authors:  Tong J Gan
Journal:  CNS Drugs       Date:  2005       Impact factor: 5.749

Review 7.  Factors influencing the choice of 5-HT3-receptor antagonist antiemetics: focus on elderly cancer patients.

Authors:  Cesare Gridelli; Matti Aapro
Journal:  Support Care Cancer       Date:  2004-03-04       Impact factor: 3.603

8.  Oxidation of celecoxib by polymorphic cytochrome P450 2C9 and alcohol dehydrogenase.

Authors:  Mia Sandberg; Umit Yasar; Patrik Strömberg; Jan-Olov Höög; Erik Eliasson
Journal:  Br J Clin Pharmacol       Date:  2002-10       Impact factor: 4.335

9.  Current position of 5HT3 antagonists and the additional value of NK1 antagonists; a new class of antiemetics.

Authors:  R de Wit
Journal:  Br J Cancer       Date:  2003-06-16       Impact factor: 7.640

10.  Effect of casopitant, a novel NK-1 antagonist, on the pharmacokinetics of dolasetron and granisetron.

Authors:  Laurel M Adams; Brendan Johnson; Ke Zhang; Lin Yue; Lyndon C Kirby; Peter Lebowitz; Randall Stoltz
Journal:  Support Care Cancer       Date:  2009-02-10       Impact factor: 3.603

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.